Mao Inhibitors + Quizartinib Interaction
Moderateinteraction on record
Description
Concomitant use increases quizartinib systemic exposure, which may increase risk of adverse reactions. VANFLYTA dosage reduction recommended.
Mechanism
CYP3A inhibition increases systemic exposure
Source: NLP:quizartinib